This Article Full Text Full Text (PDF) All Versions of this Article: 38/11/3055    most recent STROKEAHA.107.488536v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saver, J. L. Search for Related Content PubMed PubMed Citation Articles by Saver, J. L. Related Collections Health policy and outcome research Acute Cerebral Infarction Emergency treatment of Stroke Neuroprotectors Thrombolysis

(Stroke. 2007;38:3055.)
© 2007 American Heart Association, Inc.

Comments, Opinions, and Reviews

Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials

From Stroke Center and Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, Calif.

Correspondence to Jeffrey L. Saver, MD, UCLA Stroke Center, 710 Westwood Plaza, Los Angeles, CA 90095. E-mail jsaver{at}ucla.edu

Background and Purpose— Stroke treatments are generally not curative, but rather alter patient outcome over the entire range of functional measures. Dichotomizing outcome scales reduces computational complexity, but discards substantial outcome information, artificially privileges only a single health state transition as clinically meaningful, and often reduces study power. Newer approaches to endpoint analysis have several advantageous properties.

Summary of Review— The global statistic assesses treatment effects on multiple outcome measures simultaneously. However, translating the global statistic multidimensional vector effect at the population level into benefit or harm expected in the individual patient is problematic. Responder analysis adjusts outcome thresholds to patient stroke severity at study entry, identifying achievable goals for each patient. However, responder analysis still discards substantial outcome information. Shift analysis gauges change in outcome distributions over the full range of ascertained outcomes, incorporating benefit and harm at all health state transitions valued by patients and clinicians, and often increasing study power. Translation of findings of shift analyses into clinically accessible terms may be accomplished using the recently developed joint outcome table specification technique, which yields the following values for the number needed to treat for 1 patient to improve in a clinically important manner: nimodipine in subarachnoid hemorrhage, 6.8; coiling over clipping, 5.9; intra-arterial pro-urokinase in acute cerebral ischemia, 4.8; intravenous tissue plasminogen activator, 3.3.

Conclusions— Dichotomized, global statistic, responder, and shift analyses each offer distinctive benefits and drawbacks. Choice of primary end point analytic technique should be tailored to the study population, expected treatment response, and study purpose. Shift analysis generally provides the most comprehensive index of a treatment’s clinical impact.

Key Words: cerebral hemorrhage • cerebral infarction • cerebrovascular accident • clinical trials • research design

This article has been cited by other articles:

				K. T. Kreiter, S. A. Mayer, G. Howard, V. Knappertz, D. Ilodigwe, M. A. Sloan, and R. L. Macdonald Sample Size Estimates for Clinical Trials of Vasospasm in Subarachnoid Hemorrhage Stroke, July 1, 2009; 40(7): 2362 - 2367. [Abstract] [Full Text] [PDF]

				J. L. Saver, J. Gornbein, J. Grotta, D. Liebeskind, H. Lutsep, L. Schwamm, P. Scott, and S. Starkman Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial Stroke, July 1, 2009; 40(7): 2433 - 2437. [Abstract] [Full Text] [PDF]

				M. G. Lansberg, M. Schrooten, E. Bluhmki, V. N. Thijs, and J. L. Saver Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale Stroke, June 1, 2009; 40(6): 2079 - 2084. [Abstract] [Full Text] [PDF]

				P. Mandava and T. A. Kent A Method to Determine Stroke Trial Success Using Multidimensional Pooled Control Functions Stroke, May 1, 2009; 40(5): 1803 - 1810. [Abstract] [Full Text] [PDF]

				A. G. Rudd and L. S. Williams Advances in Health Policy and Outcomes Stroke, May 1, 2009; 40(5): e301 - e304. [Full Text] [PDF]

				J. L. Saver and J. Gornbein Treatment effects for which shift or binary analyses are advantageous in acute stroke trials Neurology, April 14, 2009; 72(15): 1310 - 1315. [Abstract] [Full Text] [PDF]